EnteroBiotix appoints Elmar Schnee as Executive Chairman
17 juil. 2023 03h00 HE
|
EnteroBiotix
GLASGOW, Scotland, July 17, 2023 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the...
Biotech Executive Beth Thompson-Webb Joins Culture Biosciences’ Board of Directors
13 juil. 2023 06h33 HE
|
Culture Biosciences
BOSTON, July 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences has appointed Beth Thompson-Webb, Chief Commercial Officer at Virica Biotech, as Independent Director to the company’s Board of...
SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer
13 juil. 2023 04h00 HE
|
SiSaf Ltd
GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in the Treatment of Children with Newly Diagnosed Diffuse Midline Gliomas (DMGs)
10 juil. 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
10 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Completion of Enrolment and Treatment in the Phase 1 Study of MTX110 in theTreatment of Children with Newly Diagnosed Diffuse Midline Gliomas...
Results of Appeal of Delisting Determination
06 juil. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical...
Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG)
06 juil. 2023 08h15 HE
|
Biodexa Pharmaceuticals PLC
6 July 2023 Biodexa Ltd(“Biodexa” or the “Company”) Publication of Manuscript from the PNOC015 (a.k.a. MTD-201) Study in Patients with Diffuse Midline Glioma (DMG) Biodexa Pharmaceuticals PLC...
ADR Ratio Change
22 juin 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
22 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of...
Appeal of Delisting Determination
20 juin 2023 08h00 HE
|
Biodexa Pharmaceuticals PLC
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company...
Culture Biosciences and Cytiva team up to innovate in upstream bioprocessing to advance the development and manufacturing of new therapies
15 juin 2023 07h00 HE
|
Culture Biosciences
BOSTON, June 15, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences and Cytiva are collaborating to advance innovation in upstream bioprocessing by providing customers greater access to predictive and...
US Capital Global Securities Launches $5 Million Equity Offering for Canadian Health Science Pioneer Andira Pharmaceuticals
14 juin 2023 09h00 HE
|
US Capital Global
San Francisco, California, USA, June 14, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, is offering eligible investors an investment opportunity of up...